Is UZEDY Approved for Bipolar Disorder?
No, UZEDY (risperidone extended-release injectable suspension) is FDA-approved only for schizophrenia in adults.[1] It is not approved for bipolar disorder or any other condition.
What Is UZEDY Used For?
UZEDY delivers risperidone monthly or every two months via subcutaneous injection. The FDA approved it in 2023 for maintenance treatment of schizophrenia, reducing relapse risk compared to placebo.[1][2] Risperidone itself has broader approvals (oral form for bipolar mania), but UZEDY's long-acting formulation is limited to schizophrenia.
Off-Label Use for Bipolar Disorder?
No established evidence supports UZEDY specifically for bipolar disorder. While oral risperidone treats acute manic or mixed episodes in bipolar I disorder, no clinical trials test UZEDY's subcutaneous delivery for bipolar maintenance or mania.[3] Prescribing off-label carries risks like unknown dosing efficacy and side effects in bipolar patients.
What Happens If Used Off-Label Anyway?
Potential benefits mirror oral risperidone (mood stabilization), but lack of data means uncertain long-term safety for bipolar cycling. Common risperidone risks include weight gain, sedation, extrapyramidal symptoms, and hyperprolactinemia—amplified in bipolar patients on mood stabilizers.[4] Consult a psychiatrist; guidelines prioritize FDA-approved long-acting injectables like risperidone (Risperdal Consta) or aripiprazole (Abilify Maintena) for bipolar if indicated.
Alternatives for Bipolar Disorder Maintenance
- Approved long-acting antipsychotics: Aripiprazole (Abilify Maintena/Maintenance), risperidone (Risperdal Consta), paliperidone (Invega Sustenna/Hafyera).
- Oral options: Lithium, valproate, lamotrigine, quetiapine.
- Why not UZEDY? Easier subcutaneous administration than intramuscular alternatives, but no bipolar data limits adoption.[5]
Who Makes UZEDY and Patent Status?
Teva Pharmaceuticals and MedinCell developed UZEDY using SteadyTeq technology. Key U.S. patents expire around 2037-2040; check DrugPatentWatch.com for challenges or generics.6
[1]: FDA Label - UZEDY (uzedyhcp.com)
[2]: PMDA Approval Summary (2023)
[3]: ClinicalTrials.gov (no bipolar trials for UZEDY)
[4]: APA Bipolar Guidelines (2020)
[5]: Lancet Psychiatry Review on LAIs (2022)